INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates ...

INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study...

INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Web...

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia...

INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update...

INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at t...

INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society...

INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Co...

CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Pres...

INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 Alzhe...

INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate...

INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for...

INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September...

INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual ...

INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update...

INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member...

INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer...

INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immu...

INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Scien...

INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Disease...

INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ON...

INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference...

INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th...

INmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capit...

INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update...

INmune Bio Closes Private Placement of Approximately $4.1 Million of Common Stock, Led by Insiders a...

INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit...

INmune Bio Co-Founder and CEO to Speak at Cambridge Healthtech Institute’s 10th Annual Inflammatio...

INmune Bio Announces Poster Presentation with New Data Regarding Neurodegenerative Disease Drug Cand...

INmune Bio to Ring the NASDAQ Closing Bell on Tuesday, April 9, 2019...

INmune Bio Co-Founder and CEO Presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Onco...

INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics S...

INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer...

INmune Bio to Present at BIO CEO & Investor Conference...

INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Marke...

INmune Bio, Inc. Announces Pricing of Initial Public Offering...